Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Amsterdam Immunogenicity and Tolerance
Document related concepts
Transcript
Amsterdam Immunogenicity and Tolerance Seminar 2016 Venue: Hilton Apollolaan Apollolaan 138, 1077 BG Amsterdam, Netherlands Session Moderator: Oréda Boussadia, PhD, MBA European Head of Business Development and Strategy EpiVax, Inc. Speakers: Prof. Annie De Groot, MD Professor and Director, Institute of Immunology and Informatics, University of Rhode Island, CEO/CSO, EpiVax, Inc. Wim Jiskoot, PhD Professor of Drug Development Leiden University Medical Center Tom Ottenhoff, MD, PhD Professor of Immunology Leiden University Medical Center Marieke Van Ham, PhD Immunopathology Department Head Sanquin Laurent Mascarell, PhD Head of Pre-clinical Immunology and Molecular Biology Stallergenes Kees Melief, PhD Chief Scientific Officer ISA Pharma Elly Van Riet, PhD Senior Scientist Intravacc For more information visit our event page: http://bit.ly/EpiVax_Immunogenicity_Seminar_AMS_2016 Conference Agenda EpiVax Immunogenicity and Tolerance Seminar October 24th 2016 Time Presenter 9:30 10:00 10:30 Anne S. De Groot MD CEO/CSO EpiVax Kees Melief, PhD Chief Scientific Officer ISA Pharma 11:00 Topic Arrival and Coffee Room Assignment TBD Introduction and Purpose of the Meeting: What Drives Immunogenicity of Vaccines and Biologics: New Hypotheses and Recent Studies In Vivo Studies: Recent Data from ISA Epitope-driven Cancer Vaccine Trials Break (30 minutes) 11:30 Marieke Van Ham, PhD Immunopathology Sanquin In Vitro Studies using Human Donor T cells: CD4 T-cell responses against the therapeutic antibody adalimumab in Rheumatoid Arthritis patients 12:00 Wim Jiskoot, PhD Professor of Drug Development Leiden University Medical Center Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges 12:30 Tom Ottenhoff MD, PhD Professor of Immunology Leiden University Medical Center 1:00 1:30 2:00 2:30 Future Vaccine Development: Regulatory T cells in Tuberculosis: Friend or Foe? Lunch (60 minutes) Laurent Mascarell, PhD Head of Pre-clinical Immunology and Molecular Biology Stallergenes Elly Van Riet, PhD Senior Scientist Intravacc Annie De Groot, MD Director of Analysis Frances Terry, MPH EpiVax 3:00 Clinical Trial Monitoring: Biomarkers for Tolerance Future Vaccine Development: Immunogenicity of a Pertussis Outer Membrane Vesicle Vaccine Live Demonstration of ISPRI/iVAX Approach: Design and Optimization of Vaccines and Biologics Break (30 minutes) Panel Discussion and Questions Topic: Relevance of Today’s Talks to Design and Development of Biologics and Vaccines (for Infectious Diseases, Allergy and Cancer) 3:30 All Speakers 4:30 Speakers and Attendees Award presentation 5:00 Speakers and Attendees Networking session For more information visit our event page: http://bit.ly/EpiVax_Immunogenicity_Seminar_AMS_2016 EpiVax: The team at EpiVax, Inc., led by Dr. Annie De Groot and Bill Martin, has pioneered the development of a set of immunoinformatics tools which allows researchers to predict the immunogenicity of peptides and proteins. The potential applications of this technology are vast: for instance, one could be to predict which vaccines will be most effective or which protein therapeutic drugs will have the possibility of eliciting an adverse immune response. It is a powerful research and development tool for designing effective and safe protein/peptide based therapeutics. The leaders of EpiVax, Inc. have been resolute in availing these tools to the research community. To that end, Dr. De Groot and her team, with funding from an NIH U19 grant, have developed the iVAX website where investigators can access their own set of genome sequences, proteins of interest, and tools for the analysis of vaccines and diagnostics. Using the iVAX toolkit, researchers can quickly and efficiently identify the most reactive proteins contained within a given pathogen, and optimize the antigenic content of vaccines. Furthermore, by selecting the highest quality epitopes from a protein sequence new antigens that are relevant for vaccine development can be discovered. For more information visit our event page: http://bit.ly/EpiVax_Immunogenicity_Seminar_AMS_2016
